Acorda Therapeutics, Inc. reaffirmed revenue guidance for the full year 2023. For the period, the company reaffirms net revenue to be $65 million to $70 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.73 USD | -2.67% | +92.11% | -95.16% |
Apr. 15 | Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market | MT |
2023 | Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023 |
1st Jan change | Capi. | |
---|---|---|
-95.16% | 529K | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ACOR.Q Stock
- ACOR Stock
- News Acorda Therapeutics, Inc.
- Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023